Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News about ARMP centers on its late clinical-stage phage pipeline, including AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa, FDA designations and regulatory interactions, scientific publications on phage structure, and clinical program updates.
Company updates also cover financial results, research and development spending, grant-supported program activity, credit agreement and warrant amendments with Innoviva-related entities, and board or annual-meeting governance matters. Armata describes in-house phage-specific cGMP manufacturing as part of its development model.
Armata Pharmaceuticals (NYSE: ARMP) reported Q4 and full-year 2024 results, highlighting significant clinical progress. The company announced positive topline results from its Phase 2 Tailwind study of inhaled AP-PA02 for treating Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis patients, showing statistically significant bacterial reduction.
Q4 2024 financial highlights include:
- Grant revenue of $1.2M (vs $1.5M in Q4 2023)
- R&D expenses of $8.5M (vs $7.9M in Q4 2023)
- Net income of $2.6M or $0.07 per basic share
- Cash position of $14.8M as of December 31, 2024
The company secured a $10M secured credit agreement with Innoviva Strategic Opportunities in March 2025. Armata also completed enrollment in its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia, with topline results expected in H1 2025.
Armata Pharmaceuticals (NYSE American: ARMP) has secured a $10 million credit agreement with Innoviva Strategic Opportunities , its largest shareholder. The loan facility comes with a 14.0% annual interest rate and matures on March 12, 2026.
The proceeds will support the development of Armata's lead therapeutic phage candidates: AP-PA02 targeting Pseudomonas aeruginosa infections and AP-SA02 for Staphylococcus aureus infections. The funding will specifically enable the company to complete its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia and prepare for an end-of-Phase 2 FDA meeting.
Additionally, Armata amended three existing credit agreements with Innoviva, extending their maturity dates to March 12, 2026. The company continues to seek additional funding sources, including non-dilutive options, to support late-stage clinical trials.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics, has announced that CEO Dr. Deborah Birx will present at the 7th Annual Bacteriophage Therapy Summit in Boston, MA. The presentation is scheduled for Thursday, March 13, 2025, at 9:00am ET.
The company focuses on developing high-purity pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and difficult-to-treat bacterial infections.
Armata Pharmaceuticals (NYSE: ARMP) announced positive topline results from its Phase 2 Tailwind trial of AP-PA02, an inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients.
The trial demonstrated statistically significant reduction of P. aeruginosa in lung sputum, with effects persisting two weeks after treatment completion. A post-hoc analysis showed significant bacterial reduction at day 17 (P=0.05) and day 24 (P=0.015) compared to placebo. Approximately one-third of subjects treated with phage monotherapy showed at least a 2-log CFU reduction.
The treatment was well-tolerated with mostly mild adverse events, though one possibly related serious adverse event requiring hospitalization was reported. The study suggests AP-PA02 alone could be as effective as combination therapy with antibiotics.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.
Armata Pharmaceuticals announced Q3 2024 results and key developments. The company completed enrollment in two significant clinical trials: the Phase 2 'Tailwind' study of inhaled AP-PA02 for non-cystic fibrosis bronchiectasis, with topline data expected by year-end, and the Phase 1b/2a 'diSArm' study of intravenous AP-SA02 for S. aureus bacteremia, with results expected in Q1 2025. Financial highlights include grant revenue of $3.0M, R&D expenses of $9.5M, and a net loss of $5.5M ($0.15 per share). The company held $17.1M in cash as of September 30, 2024.
Armata Pharmaceuticals (NYSE American: ARMP) has completed enrollment (n=50) for its Phase 1b/2a diSArm study of intravenous AP-SA02, targeting Staphylococcus aureus bacteremia. The study aims to assess the safety, tolerability, and efficacy of AP-SA02, a bacteriophage therapy, as an adjunct to standard antibiotics. Armata expects topline data in Q1 2025, which could support the initiation of a pivotal efficacy trial later that year. Initial findings show no significant adverse events and evidence of in vivo phage amplification in half of the treated subjects. The study is backed by $21.6 million from the Defense Health Agency and the Joint Warfighter Medical Research Program.
Armata Pharmaceuticals (NYSE American: ARMP) announced a publication in Communications Biology describing the structure of phage Pa193, a key component of their multi-phage clinical candidate AP-PA02. The study, utilizing cryogenic electron microscopy, focuses on treating Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF) or non-cystic fibrosis bronchiectasis (NCFB). The research provides detailed structural analysis at single atom resolution, offering insights into phage stability and genome-delivery mechanisms. This understanding could potentially expand clinical applications to other pathogens beyond P. aeruginosa.
Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is set to take place in New York from September 9-11, 2024.
Dr. Deborah Birx, Armata's Chief Executive Officer, will deliver a corporate presentation on Wednesday, September 11, from 8:00-8:30 AM ET. This presentation offers an opportunity for investors to gain insights into Armata's innovative approach to treating difficult-to-treat bacterial infections using high-purity, pathogen-specific bacteriophage therapeutics.
Armata Pharmaceuticals (NYSE American: ARMP) announced a poster presentation at the 2024 Military Health System Research Symposium. The presentation highlights two phage development programs: inhaled AP-PA02 for Pseudomonas aeruginosa bronchiectasis and intravenous AP-SA02 for Staphylococcus aureus bacteremia. The company is 80% through enrollment in its Phase 1b/2a study (diSArm) of AP-SA02, expecting completion by end of 2024. AP-SA02 development is supported by a $21.6 million Department of Defense grant. Both phage candidates have been well-tolerated in clinical trials, allowing for higher doses. Armata plans to advance both candidates to pivotal Phase 3 trials in 2025. Preliminary data suggests intravenous AP-SA02 is active in all subjects, with longer persistence in some, potentially indicating in vivo amplification. Inhaled AP-PA02 shows promise as an alternative to inhaled antibiotics for P. aeruginosa bronchiectasis.